Advanced Filters
noise

lewy-body-disease Clinical Trials

A listing of lewy-body-disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 48 clinical trials
P Persevere Study Team

PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia

Lewy Body Dementia (LBD) is the second most common form of degenerative dementia, affecting at least 2.4 million US adults, and the overwhelming majority of persons living with LBD (PLBD) are cared for by family caregivers. LBD caregiver strain: 1) exceeds that of non-LBD dementia caregivers; 2) worsens caregiver physical …

18 - 100 years of age Both Phase N/A
R R. John Sawyer, MD

The Care Ecosystem Consortium Effectiveness Study

The Care Ecosystem is an accessible, remotely delivered team-based dementia care model, designed to add value for patients, providers and payers in complex organizational and reimbursement structures. Care is delivered via the phone and web by unlicensed Care Team Navigators, who are trained and supervised by a team of dementia …

18 - 100 years of age Both Phase N/A
J Jonathan Abele, MD

18F-DOPA II - PET Imaging Optimization

A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: Pediatric patients (less than 18 years old) with congenital hyperinsulinism. Pediatric patients (less than 18 years old) with neuroblastoma. Pediatric (less than 18 years old) or Adult patients (18 or older) with …

- 100 years of age Both Phase 3
B Benzi Kluger, MD

Community Outreach for Palliative Engagement -- Parkinson Disease

The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care is a treatment approach focused on …

40 - 100 years of age Both Phase N/A
R Research Coordinator

Trial of Parkinson's and Zoledronic Acid

This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will …

60 - 100 years of age Both Phase 4
E Erik Stomrud, MD, PhD

The Swedish BioFINDER 2 Study

The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in …

20 - 100 years of age Both Phase N/A
S Sarah Horn, MD

Comparing Antipsychotic Medications in LBD Over Time

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to …

- 100 years of age Both Phase 4
S Suzanne Reeves

Trial of Ondansetron as a Parkinson's HAllucinations Treatment

TOPHAT (Trial of Ondansetron as a Parkinson's HAllucinations Treatment) is a double blind, individually randomized, placebo-controlled, parallel group, flexible dose trial of ondansetron (8-24mg/day) as a treatment for Parkinson's hallucinations, with a 12-week primary outcome and follow-up to 24 weeks.

18 - 100 years of age Both Phase 2
A Arvid Rongve, Phd

Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial

This is a confirmatory investigational medicinal product (IMP) study to investigate the effects on cognition, functional decline and on neuropsychiatric symptoms of the Glucocerebrosidase (GCase) enhancing chaperone ambroxol in participants diagnosed with prodromal and early dementia with Lewybodies (DLB).

50 - 85 years of age Both Phase 2
E Eileen Robinson

Stimulation of Cingulo-opercular Alertness Network

Fluctuations in alertness are very common in persons with Lewy body dementias and are a major source of disability. Changes in a chemical messenger molecule called acetylcholine within certain brain regions may play a role in these fluctuations. We propose to test this hypothesis and also determine whether a non-invasive …

50 - 90 years of age Both Phase N/A

Rewrite in simple language using AI